Royalty Pharma plc
Royalty Pharma plc (RPRX): 65 pipeline candidates · 4 upcoming catalysts · ~13 mo cash runway · 29 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
12.8 months
N/A
Lead: Approved
65 candidates
4 upcoming, next in ~847d
0 buys · 32 sells (180d)
A transparent, data-derived signal for Royalty Pharma plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$30.9B
Cash
$586.4M
Quarterly Burn
$199.3M
Runway
12.8 mo
Revenue
$630.6M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (65 candidates)
| Drug | Phase |
|---|---|
| [²¹²Pb]Pb-ADVC001 | Phase 1 |
| Abiraterone acetate | Phase 1 |
| Acarbose Tablets | Phase 2 |
| Ampreloxetine | Phase 3 |
| Amvuttra | Approved |
| Androgen Deprivation Therapy | Phase 4 |
| Androgen-deprivation Therapy | Phase 4 |
| Antiandrogen | Phase 2 |
| Antiandrogen Therapy | Phase 2 |
| Apalutamide | Phase 4 |
Showing 10 of 65 candidates. Sign up for full pipeline.
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
582
Total value held
$13.50B
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 43,571,633 | $2.09B |
| blackrock, inc. | 25,907,745 | $1.24B |
| fmr llc | 25,152,242 | $1.21B |
| state street corp | 10,989,851 | $527.2M |
| vanguard capital management llc | 9,063,772 | $434.8M |
| geode capital management, llc | 7,869,632 | $376.5M |
| adage capital partners gp, l.l.c. | 7,480,633 | $358.8M |
| caledonia (private) investments pty ltd | 7,168,399 | $343.9M |
| victory capital management inc | 3,853,808 | $184.9M |
| northern trust corp | 3,808,735 | $182.7M |
Showing top 10 of 582 institutional holders of Royalty Pharma plc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Royalty Pharma plc's pipeline?
Royalty Pharma plc (RPRX) has 65 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Royalty Pharma plc's lead drug candidate?
Royalty Pharma plc's most advanced tracked candidate is [²¹²Pb]Pb-ADVC001 (Phase 1) for Prostate Cancer.
What is Royalty Pharma plc's next catalyst?
Royalty Pharma plc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermitte" — expected October 12, 2028.
What is Royalty Pharma plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Royalty Pharma plc has approximately 12.8 months of cash runway.
What is Royalty Pharma plc's market capitalization?
Royalty Pharma plc's market capitalization is approximately $30.9B.
Get the full picture on Royalty Pharma plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.